{"analyses":[{"ciLowerLimit":"2.01","ciPctValue":"95","ciUpperLimit":"7.15","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","paramType":"Hazard Ratio (HR)","paramValue":"3.79","statisticalComment":"Stratified by cancer type and screening uNTx level","statisticalMethod":"Regression, Cox","testedNonInferiority":false},{"ciLowerLimit":"2.23","ciPctValue":"95","ciUpperLimit":"8.36","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","paramType":"Hazard Ratio (HR)","paramValue":"4.32","statisticalComment":"Stratified by cancer type and screening uNTx level","statisticalMethod":"Regression, Cox","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8","upperLimit":"141","value":"65"},{"groupId":"OG001","lowerLimit":"4","upperLimit":"11","value":"9"},{"groupId":"OG002","lowerLimit":"8","upperLimit":"11","value":"10"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"33"},{"groupId":"OG002","value":"36"}],"units":"Participants"}],"description":"Kaplan-Meier estimate of the median time from enrollment to the 1st occurrence of uNTx below 50 nmol BCE/mmol (corrected by creatinine) up to week 25. For participants whose uNTx does not go below 50 nM BCE/mM creatinine, the time is censored at time of last evaluation of uNTx by week 25.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Open-label intravenous (IV) bisphosphonate once every 4 weeks (Q4W)","id":"OG000","title":"Bisphosphonate IV Q4W"},{"description":"Open-label denosumab 180 mg by subcutaneous injection once every 12 weeks (Q12W)","id":"OG001","title":"Denosumab 180 mg Q12W"},{"description":"Open-label denosumab 180 mg by subcutaneous injection once every 4 weeks (Q4W)","id":"OG002","title":"Denosumab 180 mg Q4W"}],"paramType":"MEDIAN","populationDescription":"All participants who are randomized to the treatment phase, receive at least one dose of treatment phase investigational product, and have treatment phase baseline measurements of uNTx and at least one treatment phase post-baseline measurement of uNTx.","reportingStatus":"POSTED","timeFrame":"Day 1, week 25","title":"Time to Reduction of uNTX (Corrected by Creatinine) to <50nmol/mmol","type":"SECONDARY","unitOfMeasure":"Days"}